Japanese pharmaceutical company Shionogi’s new oral COVID-19 drug has achieved the primary endpoint in a clinical trial, the company announced in September.
From February to July, Shionogi conducted a clinical trial with 1,821 people to evaluate ensitrelvir fumaric acid (S-217622), the oral drug the company developed in February. The subjects were not at risk for other diseases and had been vaccinated.
